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Fragility fractures of the hip (FFH) constitute the most serious complication of 
osteoporosis carrying a mortality rate of up to 20 – 30% in the first year after 
injury and are associated with post injury decay in patient’s level of activity in 
more than 50% of the cases. It is also a predictor of future osteoporosis 
related fractures. 
Surgical fixation of the hip fracture within 48 hours of admission, multimodal 
pain management, deep vein thrombo-prophylaxis, early physical therapy, 
appropriate assessment and management of osteoporosis and frailty in a 
multidisciplinary approach are the standard of care for FFH to keep the 
mortality and morbidity rate as low as possible and prevent future fragility 
fractures. 
Aim 
To assess the standard of care of FFH at our institution and determine areas 
of care which need more attention and improvement. 
Methods 
Retrospective review of clinical and radiographic records of all patients 
admitted at our level 1 trauma unit for fragility fracture of the hip from 1st 
January 2014 to 31st December 2014. 
The waiting time from admission to surgical fixation of the hip fracture, pain 
control and thrombo-prophylaxis strategies, the rate of geriatric referrals and 
the extent of osteoporosis management were assessed. 
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Results 
We admitted 113 fragility fractures of the hip from 1st January to 31st 
December 2014, 98 clinical records and 98 pelvis radiographs were included 
in the study. The other 15 clinical records were incomplete and were 
therefore excluded. 
The average waiting time from admission to surgery was 49 hours (range 9 -
120). All patients received low dose morphine, paracetamol and tramadol for 
perioperative pain control. Low molecular weight heparin and compression 
stockings were prescribed for thrombo-prophylaxis in all patients. 
Only 2 (2, 04%) patients had some osteoporosis investigations ordered and 
none of the patients were referred to the geriatric department, none of them 
were formally treated for osteoporosis. 
Conclusion 
While the waiting time from admission to surgery was largely within the 
recommended time frame, there were no signs of a multidisciplinary 
approach to the management of fragility fractures of the hip at our institution 
leaving osteoporosis and frailty largely untreated. 
Key words: fragility fracture, geriatric hip fracture, hip fractures standard of 
care, osteoporosis, frailty care. 
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PART A - RESEARCH PROTOCOL
THE MANAGEMENT OF FRAGILITY FRACTURES OF THE HIP: A 
QUALITY ASSESSMENT PROJECT. 
MMed student: Dr Ntambue Kauta 
Supervisor: Dr Sithombo Maqungo 
Co-investigators: Dr M Held, Dr S Dlamini, Dr S Kalula, Dr I Ross, Dr G Kalla 
I. INTRODUCTION
Fragility fractures of the hip (FFH) are defined as fractures due to a low 
energy trauma such as falling from standing height as a result of a decrease 
in bone mass. These fractures are commonly seen in old age and are 
recognised as complications of osteoporosis in its various forms.1 The 
incidence of FFH is expected to continue rising due to the ever increasing life 
expectancy seen across developed and emerging countries worldwide. 
It is estimated that 1 in 3 postmenopausal women and 1 in 5 men over the 
age of 75 will suffer a FFH in their life time. The rising global prevalence of 
FFH is estimated to reach 2.6 million in 2025 and 6.3 million by year 2050.2 
FFH constitutes the most serious complication of osteoporosis carrying a 
mortality rate of up to 20 – 24% in the first year after injury and is associated 
with post injury decline in patients’ level of activity in more than 50% of the 
cases.2,3 
The understanding that patients affected by FFH often present with a 
background of significant medical co-morbidities and frailty has led to the 
development of strict management  guidelines with emphasis on a 
multidisciplinary approach to improve survival rate and clinical outcome after 
a FFH. 
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The American Academy of Orthopaedic Surgeons clinical practice guidelines 
stipulate that surgical fixation of the hip fracture within 48 hours of admission 
coupled with multimodal pain treatment, DVT prophylaxis, frailty care and 
osteoporosis management will ensure a positive clinical outcome. The pre-
surgery waiting time should only be allowed for medical management of 
unstable or uncontrolled co-morbid conditions.4 
Studies have shown a tendency to neglect the management of osteoporosis 
and frailty in patients who have been treated for FFH at various orthopaedic 
centres across the world with only 2% to 8 % of these patients being referred 
for osteoporosis treatment.3, 5 
The purpose of our study is to evaluate the standard of management of 
fragility fractures of the hip at our institution by determining the waiting time 
from admission to surgical fixation of the fracture, the common mode of 
analgesia and  DVT prophylaxis and management of osteoporosis and frailty. 
II. METHODS
Retrospective review of clinical and radiographic records of all patients 
treated at our institution for fragility fractures of the hip from the 1st of January 
2014 to 31st December 2014. 
Patient’s details were obtained from our admissions records and matched 
with details on our surgical database. We were able to retrieve their folders 
from our records department and their radiographs were available on our 
digital PACS (Picture archiving and communication system). 
Folders were examined to determine the waiting time from admission to 
surgical fixation of the fracture, the common mode of analgesia and DVT 
prophylaxis, the rate of geriatric referrals and the extent of management of 
osteoporosis and frailty. 
Inclusion criteria 
x Hip fracture sustained from a fall from standing height or lower. 
x Availability of patient’s folder with clearly documented mechanism of 
injury, date and time of admission, date and time of surgery and x-rays 
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Exclusion criteria 
x High energy hip fractures 
x Pathological hip fractures due to malignant lesions or infection 
x Incomplete records 
Study measures 
Patient’s records were reviewed to determine the following measures: 
x In hospital or postoperative out-patients investigations for osteoporosis 
(DEXA Scan, erythrocyte sedimentation rate(ESR), thyroid stimulating 
hormone(TSH), parathyroid hormone(PTH), Serum Protein 
electrophoresis, Calcium and vitamin D levels) 
x Time to surgery in hours 
x In hospital prescription of low molecular weight heparin(Enoxaparin) 
x Inpatient or outpatient prescription of vitamin D and calcium 
x Inpatient or outpatient prescription of anti-resorptive treatment 
III. STUDY RELEVANCE
This study is aimed at determining our level of care for fragility fractures of 
the hip. It will identify weaknesses in our management strategies and 
recommendations will be made to improve our current treatment protocol. 
IV. REPORT OF FINDINGS
The results will be submitted for publication in a peer review journal (South 
African Orthopaedic Journal) and will also be discussed at the South African 
orthopaedic congress and research or faculty meetings. 
V. BUDGET AND FUNDING
Costs not requiring funding: 
Departmental and personal computer usage. 
Paper, stationery and photocopying supplied by the Orthopaedic department 
of the University of Cape Town. 
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Researchers will not be remunerated and will do the research as part of their 
current academic appointments. 
 
VI. ETHICS 
Informed consent is not applicable to this retrospective review, no patients 
identification will be linked to any of the raw data or results. 
Risks/benefits: 
There will be no risk or any potential benefit for the patients. The medical 
records will remain confidential. The results of this study will help us identify 
and strengthen deficient aspects of management of fragility fractures of the 
hip and the publication of these results could serve as a wake up call for 
other orthopaedic units around South Africa and the world to review their own 
treatment approach for fragility fractures of the hip. 
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PART B: LITERATURE REVIEW 
 
I. OBJECTIVES OF LITERATURE REVIEW 
 
x To gain insight in the burden of fragility fractures of the hip (FFH) in 
terms of global prevalence, aetiology, current treatment guidelines and 
clinical outcome after treatment. 
x To search for existing studies which have audited the management of            
FFH in various parts of the world. 
x To gain knowledge and understanding of osteoporosis diagnosis, 
treatment and prevention. 
 
II. SEARCH METHODOLOGY 
 
Internet based search engines such as Pubmed, Medline and Google 
Scholar were used to identify articles relevant to the review. Articles were 
reviewed only if they were written in English and published in a peer 
reviewed journal. 
Online relevant textbooks were also used. 
 
III. INTRODUCTION 
A fracture that is sustained following a minimal trauma such as a fall from 
standing height is defined as a fragility fracture. These fractures are caused 
by osteoporosis in its various forms. Fragility fractures of the hip constitute 
the most severe complication of osteoporosis because of the associated high 
mortality and morbidity rate.1 
11 
 
The incidence of FFH is expected to continue rising due to the ever 
increasing life expectancy seen in developed and emerging countries across 
the globe.2 
It is estimated that 1 in 3 postmenopausal women and 1 in 5 men over the 
age of 75 will suffer a FFH in their life time. The rising global prevalence of 
FFH is estimated to reach 2.6 million in 2025 and 6.3 million by year 2050.3 
FFH constitutes the most serious complication of osteoporosis carrying a 
mortality rate of up to 20 – 24% in the first year after injury and is associated 
with post injury decline in patients’ level of activity in more than 50% of the 
cases.2 
The understanding that patients affected by FFH often present with a 
background of significant medical co-morbidities and frailty has led to the 
development of strict management  guidelines with emphasis on a 
multidisciplinary approach to improve survival rate and clinical outcome after 
a FFH. 
The American Academy of Orthopaedic Surgeons clinical practice guidelines 
stipulate that surgical fixation of the hip fracture within 48 hours of admission 
coupled with multimodal pain treatment, DVT prophylaxis, frailty care and 
osteoporosis management will ensure a positive clinical outcome. The pre-
surgery waiting time should only be allowed for medical management of 
unstable or uncontrolled co-morbid conditions.5 
Studies have shown a tendency to neglect the management of osteoporosis 
and frailty in patients who have been treated for FFH at various orthopaedic 
centres across the world with only 2 to 8 % of these patients being referred 
for osteoporosis treatment.4, 6 
While an in depth review of osteoporosis is outside the scope of this work, a 
summarized overview of osteoporosis is discussed in the subsequent 
sections of this review. 
An integrated and multidisciplinary approach is highly desirable to ensure 
that medical co-morbidities are stabilised, the acute injury is adequately 
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treated and simultaneously osteoporosis is investigated and treatment 
initiated before the patient is discharged. This comprehensive approach will 
help decrease mortality and morbidity but also serves as a secondary 
prevention of subsequent fragility fractures for the patient under treatment. 
It has been shown that such an approach is also cost effective in terms of 
preventing future hospital admissions for future fragility fractures.7 
The orthopaedic surgeon is often the first point of contact and plays a key 
role in this multidisciplinary approach. He should think beyond surgical 
fixation of the fracture and invite relevant specialties on board at the initial 
patient’s admission in the hospital. 
IV. EATIOLOGY OF FRAGILITY FRACTURES OF THE HIP 
The aetiology of fragility fractures of the hip (FFH) is multi-factorial.  
Osteoporosis represents the main aetiological factor and many other risk 
factors act together to predispose patients with osteoporosis to a fall from 
standing height or lower and fracture their hips.8, 9 
These risks factors can be classified as follow: 
1. Genetic susceptibility 
x Maternal FFH 
x Patient history of any fragility fracture 
2. Risk factors for a fall 
x Cognitive impairment 
x Visual impairment 
x Balance and gait disorders 
x Sarcopenia 
x Use of certain medication 
x Presence of environmental hazards 
 
 





The term osteoporosis derives its etymology from a combination of 2 Greek 
words, osteo (bone) and poros (porous). It is used to describe a systemic 
skeletal disorder characterized by a decrease in bone mass and a 
progressive deterioration of the bone micro-architecture predisposing to 
fragility fractures.10,11 The WHO has provided criteria for the diagnosis of 
osteoporosis and these criteria will be discussed under the diagnosis section 
of this overview. 
2. Historical perspective 
Sir Astlety Paston Cooper, a British Surgeon and Anatomist was the first to 
comment on the occurrence of fractures in subjects with abnormal bones in 
1822. In 1835 the French pathologist and surgeon Jean Lobstein was the first 
to use the term osteoporosis to describe a condition associated with blue-
grey sclera and weak bones which was probably osteogenesis imperfecta 
type I. In 1941 Fuller Albright described the cases of vertebral fractures and 
loss of height seen in women after loss of ovarian function. Oestrogen 
treatment restored calcium balance and prevented height loss.12 These 
findings were the basis of the definition of postmenopausal osteoporosis and 
established a link between osteoporosis and vertebral fractures. 
 
3. Risk factors for osteoporosis 
It is important to recognize that the peak bone mass is achieved at age 25 to 
30 and this is a crucial age group to maximize bone mass and strength. The 
peak bone mass achieved appears to be an important factor determining the 
severity and rate of bone mass decline in postmenopausal women after the 
age of 45 and men after the age of 50.8,9 
Factors negatively impacting on peak bone mass include extremes of weight 
range (underweight and obesity), inadequate physical activity, smoking, 
multiple pregnancies in women. 
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Regardless of the peak bone mass the following risk factors will predispose  
to osteoporosis: 
Age: after age 45 the ovarian function starts declining and oestrogen levels 
decline as well losing their protective effect on bone strength.  
After the age of 75 the rate of fragility fractures increases significantly in both 
woman and men.13 This is due to a higher rate of senile osteoporosis and 
frailty seen in this age group. 
Sex: women are more affected by osteoporosis because of the combination 
of post-menopausal and senile osteoporosis. 
Other factors: certain medical conditions such as celiac disease, renal 
disease, hyperparathyroidism, hypogonadism, inflammatory arthropathies 
and certain medications such as glucocorticoids will predispose patients to 
osteoporosis through various mechanisms.10 
 
4. Clinical presentation and Diagnosis 
Osteoporosis is asymptomatic and patients will only present with fragility 
fractures.8 Trabecular bones will be affected early on and in the most severe 
forms cortical bone will be affected severely enough to predispose to fragility 
fractures. Patients will then fracture their wrists many years before they get to 
fracture their hips. It has been shown that the most common pattern is to 
fracture the wrist first, followed by vertebral compression fractures and lastly 
hip fractures. This is why certain authors have described osteoporosis as a 
silent killer.14 
According to the WHO criteria, a diagnosis of osteoporosis is made when a 
patient has a T score lower than -2.5 or when a patient presents with a 
typical fragility fracture defined as a fracture occurring after a fall from 
standing height or lower and with clear osteopenia on plain radiographs. 
 A T score is obtained by measuring the patient bone mineral density (BMD) 
using a Dual-Energy X-ray Absorptiometry (DEXA) scan at the hip and the 
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spine and comparing it to a mean of young healthy Caucasian women.9 Bone 
strength depends on bone density and bone quality. Only bone density can 
be measured at this stage and it is expressed as grams of mineral per 
scanned area (g/cm2).10 
Ideally Osteoporosis is diagnosed if the patient’s T score is lower than -2.5 
standard deviations below the mean of young healthy population matched for 
gender and ethnicity.8,9 Due to lack of availability of data on mean bone 
mineral density for all ethnic groups the WHO allows matching the BMD of 
the patient to the mean BMD of young (21 to 29 year old) healthy white 
women.8, 9, 10 
According to the WHO, a DEXA scan report should classify the patient in one 
of the 3 categories as follows8: 
T score above -1 defines normal category 
T score between -1 and -2.5 defines the osteopenia category 
T score below -2.5 defines the osteoporosis category 
 
5. Aetiological Classification of Osteoporosis 
Osteoporosis is broadly classified in 2 major groups10: 
Primary Osteoporosis: this group is further classified in 2 types. Type I 
osteoporosis defines the group of postmenopausal osteoporosis and type II 
defines the senile osteoporosis which affects patients after the age of 75.8, 15 
Secondary Osteoporosis: this group defines osteoporosis due to a medical 
condition such as inflammatory and connective tissue disorders (rheumatoid 
arthritis, systemic lupus erythematous, etc..) or malignancies such as multiple 
myeloma, endocrinopathies such as hyperparathyroidism from various 
causes, hypogonadism, celiac disease and chronic use of certain drugs such 






6. Osteoporosis work-up 
As a general rule osteoporosis investigations start with a DEXA scan which 
provides patient's T score to make a diagnosis and to have a baseline BMD 
to monitor the response to treatment. 
Laboratory investigations will help exclude any possible causes of secondary 
osteoporosis and the following tests should be done for all patients under 





5.Vitamin D levels 
6.Protein electrophoresis for a myeloma screen when clinically suspected. 
7. Management of osteoporosis 
7.1   General principles 
Once the diagnosis has been made all efforts are directed at ruling out 
secondary causes of osteoporosis. The management plan will differ between 
the 2 main forms of osteoporosis namely primary and secondary 
osteoporosis. 
General nutritional and lifestyle modifications will apply to both primary and 
secondary osteoporosis and include: 
Regular physical activity 
A daily intake of at least 1.2 g of calcium and 800 IU of vitamin D has been 
shown to reduce the relative risk of falls and fragility fractures mostly in the 
institutionalized elderly patients than in the community dwellers.1, 17 
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Adequate protein intake. 
Smoking needs to be stopped and alcohol consumption moderated. 
Pharmacological treatment will depend on the type of primary osteoporosis 
being addressed. 
Postmenopausal osteoporosis will benefit from hormone replacement therapy 
early on but as senile osteoporosis sets in anti-resorptive therapy will be 
required to maintain adequate bone density. 
7.2 Bisphosphonate therapy for osteoporosis 
Bisphosphonates are synthetic, non-hydrolysable analogues of naturally 
occurring pyrophosphates that prevent loss of bone mass by interfering with 
osteoclastic activity.  
The mechanism of action leading to inhibition of osteoclastic activity depends 
on the presence or absence of the nitrogen atom on the alkyl chain in the 
chemical structure on the drug.17 
Non Nitrogen containing bisphosphonates (etidronate, clodronate, 
tiludronate) are the earlier generation and get incorporated into the 
osteoclast’s adenosine triphosphate(ATP) inhibiting the formation of the 
osteoclast’s ruffled border(required for bone resorption) and causing cell 
apoptosis to a certain degree. Higher doses are required to produce a 
significant clinical effect. 
Nitrogen containing bisphosphonates (pamidronate, alendronate, 
risedronate, zolendronate) are the recent generation.  
Nitrogen inhibits osteoclast’s farnesyl pyrophosphate synthase (cholesterol 
pathway), GTPase and cellular membrane proteins phenylation causing cell 
apoptosis. Smaller doses produce a potent anti-resorptive activity. It is 
important to note that these nitrogen containing bisphosphonates differ in 
potency.17 
Bisphosphonates can be administered orally or intravenously and have high 
affinity for hydroxyapatite adhering to bone surfaces in areas of high 
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turnover. They are ingested by osteoclasts and the non-ingested fraction is 
excreted by kidneys. Bone residency can last up to 10 years depending on 
the individual drug in use.17 
For osteoporosis treatment oral bisphosphonates are administered either 
daily or weekly on an empty stomach and this can present a significant 
compliance challenge in the elderly patients. The most recent development of 
zolendronic acid (zolendronate) represents a very attractive option since it is 
given as a yearly intravenous injection, very appealing for the elderly patients 
to eliminate compliance issues.18 
In the setting of osteoporosis bisphosphonate therapy is indicated for patients 
with a T score below -2.5(lower than -2.5 standard deviations), those with a T 
score between –1 and -2.5 and additional risk factors for fragility fractures, 
patients presenting with recognized fragility fractures after exclusion of 
secondary causes, patients with a ten- year risk of hip fracture of ≥3% or a 
ten- year risk of major osteoporosis related fractures of ≥20% as calculated 
by the applicable Fracture Risk Assessment Tool (FRAX) 17,18. The FRAX 
tool combines patient’s specific bone mineral density and clinical risk factors 
such as age, gender, body mass index(BMI), history of fragility fractures, 
history of maternal hip fracture and current smoking status to calculate a ten-
year probability or risk of a hip or other osteoporosis related fractures for 
each patient. The FRAX index is specific for each country.19   Most common 
prescription include either Alendronate 70 mg weekly or zolendronic acid 
5mg IV yearly.16 
The fracture risk reduction expected with the use of bisphosphonates has 
been widely studied on patients with vertebral fragility fractures. Alendronate 
has proven to reduce the vertebral fracture risk by 60%.17 
The most compelling data about the hip fracture risk reduction comes from 
the HORIZON(Health Outcomes and Reduced Incidence with zolendronic 
Acid Once Yearly) trial on the use of yearly 15 minute intravenous infusions 
of 5mg zolendronic acid started within 90 days after fixation of fragility 
fractures of the hip.20 The pivotal HORIZON study showed a 70% risk 
reduction of morphometric vertebral fractures and 41% risk reduction of hip 
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fractures at 36 months with an improved overall quality of life and a reduction 
in mortality rate. Patients treated with zolendronic acid were less likely to die 
of pneumonia and arrhythmias than placebo treated patients.20                   
The mechanism underlying the later findings has not been clearly explained. 
Beside the oesophageal and gastro-intestinal upset that oral 
bisphosphonates can cause, the most feared side effects of bisphosphonates 
include atypical femur fractures, osteonecrosis of the jaw and delayed or 
impaired fracture healing.17, 18 
Atypical femur fractures 
The 2013 American Society for Bone and Mineral Research Task Force 
Revised Case Definition of Atypical Femur Fractures provides major and 
minor criteria for the diagnosis of atypical femur fracture.17 
Major criteria 
The fracture is a low energy fracture due to no trauma or minimal trauma as 
a fall from standing height or less. 
The Fracture line starts from the lateral cortex and is essentially transverse in 
its orientation but can become oblique as it progresses to the medial cortex. 
Complete fractures are not comminuted and may be associated with a medial 
spike and there is thickening of the lateral cortex at the fracture site. 
The fracture must be located either in the sub-trochanteric area or in the 
diaphysis between the sub-trochanteric area and the supracondylar flare. 
Minor criteria 
Unilateral or bilateral prodromal groin or thigh pain 
Generalized increase in diaphyseal cortex thickness 
Bilateral complete or incomplete fractures 
Delayed fracture healing 
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At least 4 major criteria need to be met to make the diagnosis of atypical 
femur fracture. Minor criteria will just strengthen the suspicion15. 
The rate of these fractures varies in the literature but the known fact is that 
the incidence shows an exponential increase with the increase in the number 
of years of continuous treatment. Data from Kaiser California reported an age 
adjusted incidence of 1.8 per 100,000 with up to 2 years of bisphosphonates 
use, 16 per 100,000 with 4 - 6 years of use and 107, 5 per 100,000 with more 
than 10 years of use.18 
To prevent the occurrence of atypical fractures the concept of “drug holiday” 
has been introduced. This concept is based on the fact that bisphosphonates 
activity last many years after the treatment has been interrupted.15 It has 
been shown that after 5 years of Alendronate treatment osteoclastic activity 
remains inhibited for an additional 5 years18 and zolendronic acid activity 
continues for an additional 3 years after 3 years of use.18 
The initiation time of drug holiday and its duration still is a debatable issue 
and this should vary with the particular bisphosphonate being used and 
patient’s additional risk factors. 
Recommendations for drug holiday from bisphosphonates 
High risk: T- score ≤ -2.5 at the hip, previous fracture of the hip or spine or 
ongoing high dose glucocorticoid: drug holiday not justified but reassess the 
need for treatment at regular intervals. 
Moderate risk: T score ≥ -2.5 at the hip, no prior history of hip or spine 
fragility fracture, consider drug holiday after 3 to 5 years of treatment with 
alendronate, risedronate and zolendronic Acid.17 
 
Osteonecrosis of the jaw 
Osteonecrosis of the jaw is defined in 2 stages. In the preclinical stage the 
diagnosis is radiographic and based on the appearance of the mandible on 
plain radiographs. In the clinical stage the diagnosis is made on 
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demonstration of an area of exposed bone in the oral cavity that fails to heal 
within 8 weeks of treatment.18 
The rate of osteonecrosis of the jaw is higher in the patients treated with 
bisphosphonates in the oncology department than for those treated for 
osteoporosis. This underlines the fact that the incidence is probably 
influenced by the combination of bisphosphonates and anti-neoplastic agents 
such as angiogenesis inhibitors and immuno-suppressors. In the 
osteoporosis treatment group the rate of osteonecrosis of the jaw is much 
lower than that of atypical femoral fractures.18, 20 
 
Impaired fracture healing 
Bisphosphonates interfere with the course of continuous bone remodelling 
and it is logical to think that in so doing bisphosphonates may impair bone 
healing. This logical concern has not been validated in the literature. 
A meta-analysis of 8 randomized controlled trials including 2,508 patients 
found no statistically significant difference in bone healing at short term (3 
months) or long term (more than 12 months) between bisphosphonates 
infusion groups and control groups. There were no statistically significant 
differences in indirect bone healing between the early bisphosphonates 
groups and delayed bisphosphonates groups. Bisphosphonates infusions 
post lumbar fusion surgery increased fusion rates and shortened time to 
fusion to 6 months post-operative21. 
 
Other recent pharmacological agents for the treatment of Osteoporosis 
Parathyroid hormone (Forteo) 
While known to induce bone resorption and hypercalcemia intermittent low 
doses of parathyroid hormone have shown an anabolic effect on bone 
metabolism promoting bone formation.22 
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Pulsatile low dose parathyroid hormone is indicated for resistant osteoporosis 
and calcium levels must be monitored during treatment. It is contraindicated 
in patients with history of Paget disease because of its potential for malignant 
transformation.22 
Denosumab (Prolia, Amgen) 
This recent pharmacological agent is a RANKL (receptor activator of nuclear 
factor-Kappa B ligand) antibody which inhibits osteoclastic activity. The 
Fracture Reduction Evaluation with denosumab Once 6 Monthly (FREEDOM) 
trial indicated that unlike bisphosphonate denosumab has a rapid onset of 
osteoclastic inhibition and bone turn over reverses soon after discontinuation 
of treatment.23 It is administered as a subcutaneous injection six-monthly and 
indicated as an alternative to bisphosphonates in the first line of treatment of 
osteoporosis. 
Strontium Ranelate (Protos) 
This is a strontium salt which activates osteoblastic activity and inhibit 
osteoclastic activity resulting in net bone formation. It is used as a daily oral 
suspension and indicated for first line treatment of patients who are not 
suitable for bisphosphonates or denosumab. Concerns about its 
cardiovascular safety profile have not been validated in current literature.24 
 
VI.    STANDARD OF CARE FOR FRAGILITY FRACTURES OF THE HIP 
The aim of treatment of fragility fractures of the hip is to restore the patient's 
pre-injury activity level while minimizing morbidity and mortality and to lay out 
a plan for secondary prevention of future fragility fractures. 
A multidisciplinary approach is required to cater for the wide variety of 
physiological disturbances that are often present and requiring treatment. 
From the moment the patient is first seen in the emergency room all 
necessary investigations are conducted, hydration status corrected and co-
morbidities controlled with the aim to get the patient to theatre within 48 
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hours. In a prospective observational study Pioli et al have shown that the 
one year mortality risk increased by 12% per day of surgical delay.25 
The emergency physician would usually refer these patients straight to the 
orthopaedic surgeon and the latter becomes a key player in the 
multidisciplinary team that will be looking after these patients. 
A review article by Ekman gives a check list of management priorities that the 
orthopaedic surgeon must satisfy while treating fragility fractures of the hip. 
This check list ensures that the patient receives a holistic, comprehensive 
treatment for a positive outcome.26 
The multidisciplinary approach is aimed at reducing the perioperative 
complications seen in patients being treated for fragility fractures of the hip. 
These complications include DVT, pulmonary infections, delirium, decubitus 
pressure ulcers and cardiovascular events. 
The current recommendations for the treatment of fragility fractures of the hip 
include 
1. Specialized pain management. 
2. DVT prophylaxis 
3. Early surgery(within 48-72 hours of injury) 
4. Early physical therapy and nutritional interventions 
5. Referral to geriatricians and endocrinologists for the management of 
frailty and osteoporosis. 
A single centre study has shown that initiation of a standardized pain control 
program including the pre-operative use of femoral nerve blocks, avoidance 
of general anaesthesia and liberal use of oral intakes(food and oral fluids) 
pre-operatively resulted in much lower rate of peri-operative complications 
(pneumonia, urinary tract infection, delirium) compared to pre-program 
rates.27 
 
A meta-analysis of prospective cohorts in Asian patients with hip fractures 
reported a DVT rate of 26% when prophylaxis was not used.28 It is therefore 




A quarter of patients admitted with fragility fractures will develop delirium. 
Predisposing factors for delirium include male gender, multiple co-
morbidities, low body mass index, prolonged surgery and general 
anaesthesia.29 Although post-operative delirium is usually transient, it will 
persist for more than 4 weeks in 20% of patients. Importantly delirium is 
associated with lower functional recovery and higher mortality rate at 1 
year.30 Therefore the prevention of delirium becomes of paramount 
importance. 
The literature supports that early referral to geriatricians is associated with 
lower rate of postoperative delirium. The geriatrician will also assess the risk 
of future falls and implement strategies to minimize or prevent falls. Factors 
such as delirium, use of psychoactive pain control agents, frequent change of 
care locations increase the risk of future falls and need to be 
addressed.30,31,32           
Sarcopenia is being increasingly recognized as an independent risk factor for 
falls and fragility fractures. It is defined by the presence of a low skeletal 
muscle mass and strength with poor physical performance.33 
Physiotherapists and dieticians work together to correct sarcopenia and 
optimize physical performance of these patients for a better clinical outcome. 
It is the orthopaedic surgeon’s responsibility to make early and appropriate 
referrals to geriatricians, physicians, endocrinologists, physical therapists and 
dieticians. These other team players will help optimize patient’s medical 
condition to allow early surgery, early rehabilitation, optimal investigations, 
prevention and treatment of peri-operative complications and lay out a plan 
for osteoporosis treatment. 
The orthopaedic surgeon is encouraged to go beyond the acute fracture care 
and ensure that osteoporosis is investigated and treated either by him/her or 
by his/her medical parteners.34 
The current literature shows that, for various reasons, less than 10% of 
patients presenting to major trauma centres with fragility fractures of the hip 
actually get a full evaluation and management of osteoporosis. 6, 34, 35,36       
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This outlines a need to increase awareness of osteoporosis management in  
orthopaedic trauma centres. 
Further studies need to be directed at ways of preventing the first fragility 
fracture of the hip. Devices such as hip protectors are being developed and 
tested.37  Newer pharmacological agents such as cathepsin K inhibitors are 
being slowly introduced for the management of osteoporosis.38 
Cathepsin K is the protease that is primarily responsible for bone matrix 
resorption caused by osteoclasts. Selective inhibition of cathepsin K 
theoretically affects only one function of osteoclasts leaving their stimulation 
of bone formation unaffected. Cathepsin K inhibitors are claimed to not only 
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Abstract 
Fragility fractures of the hip (FFH) constitute the most serious complication of 
osteoporosis carrying a mortality rate of up to 30% in the first year after 
injury. Less than 50% of affected patients will regain their pre-injury activity 
level. 
Surgical fixation of the hip fracture within 48 hours of injury, multimodal pain 
management, deep vein thrombo-prophylaxis, early physical therapy and 
simultaneous management of osteoporosis and frailty in a multidisciplinary 
approach constitute the standard of care for FFH to keep the mortality and 
morbidity rates as low as possible and prevent future fragility fractures. 
Aim 
To assess the standard of care of FFH at our institution and determine areas 
of management which require more attention and improvement. 
Methods 
Retrospective review of clinical and radiographic records of all patients 
admitted at our institution for fragility fractures of the hip from 1st January 
2014 to 31st December 2014. 
The waiting time from admission to surgical fixation of the hip fracture, pain 
control and thrombo-prophylaxis strategies, rate of geriatric referrals and 
extent of osteoporosis management were assessed. 
Results 
We admitted 113 fragility fractures of the hip from 1st January to 31st 
December 2014, 98 clinical records and 98 pelvis radiographs were included 
in the study. The other 15 clinical records were incomplete and were 
therefore excluded. 
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The average waiting time from admission to surgery was 49 hours (range 9 -
120). All patients received low dose morphine, paracetamol and tramadol for 
perioperative pain control. Low molecular weight heparin and compression 
stockings were prescribed for thrombo-prophylaxis in all patients. 
Only 2 (2, 04%) patients had some osteoporosis investigations ordered and 
none of the patients were referred to the geriatric department, none of them 
were formally treated for osteoporosis. 
Conclusion 
While the waiting time from admission to surgery was largely within the 
recommended time frame, there were no signs of a multidisciplinary 
approach to the management of fragility fractures of the hip at our institution 
leaving osteoporosis and frailty largely untreated. 
Key words: fragility fractures, hip, geriatric hip fractures, standard of care for 
hip fractures, osteoporosis, frailty care 
Introduction 
A hip fracture that is sustained following a minimal trauma such as a fall from 
standing height is defined as a fragility fracture of the hip (FFH). Fragility 
fractures of the hip are caused by osteoporosis in its various forms and 
constitute the most severe complication of osteoporosis because of the 
associated high mortality and morbidity rates.1 
The incidence of FFH is expected to continue rising due to the ever 




It is estimated that 1 in 3 postmenopausal women and 1 in 5 men over the 
age of 75 will suffer a FFH in their life time. The rising global prevalence of 
FFH is estimated to reach 2.6 million in 2025 and 6.3 million by year 20502. 
FFH carry a mortality rate of up to 30% in the first year after injury and are 
associated with a post injury decline in patients’ level of activity in more than 
50% of the cases.2,3  These factors make FFH the most serious complication 
of osteoporosis. 
The understanding that patients affected by FFH often present with a 
background of heavy medical co-morbidities and medical frailty has led to the 
development of strict management  guidelines with emphasis on a 
multidisciplinary approach to improve survival rate and clinical outcome after 
a FFH. 
The American Academy of Orthopaedic Surgeons clinical practice guidelines 
stipulate that surgical fixation of the hip fracture within 48 hours after injury 
coupled with multimodal pain treatment, deep vein 
thrombosis(DVT)prophylaxis, frailty and osteoporosis management will 
ensure a positive clinical outcome. The pre-surgery waiting time should only 
be allowed for medical management of unstable or uncontrolled co-morbid 
conditions.4 
Studies have shown a tendency to neglect the management of osteoporosis 
and frailty in patients who have been treated for FFH at various orthopaedic 
centres across the world with only 2% to 8 % of these patients being referred 
for osteoporosis treatment.5,6 
Osteoporosis is broadly classified in 2 major groups7: 
Primary Osteoporosis: this group is further classified in 2 types. Type I 
osteoporosis defines the group of postmenopausal osteoporosis and type II 
defines senile osteoporosis which affects patients after the age of 75.8,9 
Secondary Osteoporosis: this group defines osteoporosis due to a medical 
condition such as inflammatory and connective tissue disorders (rheumatoid 
arthritis, systemic lupus erythematosus, etc…) or malignancies such as 
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multiple myeloma, endocrinopathies such as hyperparathyroidism from 
various causes, hypogonadism, celiac disease and chronic use of certain 
drugs such as steroids.7,8
It is vitally important that osteoporosis, the main etiological factor of FFH be 
appropriately investigated and classified to initiate appropriate treatment. 
Alongside osteoporosis many other risk factors play a significant role in 
causing FFH. These factors need to be identified at the initial admission and 
appropriate measures taken to prevent further falls and fractures. These risk 
factors include cognitive impairment, visual impairment, balance and gait 
disorders, sarcopenia, use of neuroactive medication, history of maternal 
FFH, patient’s history of any fragility fracture.8,10
An integrated and multidisciplinary approach is highly desirable to ensure 
that medical co-morbidities are stabilised, the acute injury is adequately 
treated and simultaneously osteoporosis is investigated and its treatment 
initiated before the patient is discharged.  
This comprehensive approach will decrease mortality and morbidity and 
ensure secondary prevention of subsequent fragility fractures.  
The purpose of this study was to assess the standard of care of FFH at our 
Institution and identify areas of management that require improvement. 
Patients and methods 
We conducted a retrospective review of clinical and radiographic records of 
all patients admitted with a fragility fracture of the hip at our level 1 trauma 
unit from 1st January 2014 to 31st December 2014. 
Patients’ details were obtained from our admissions records and matched 
with details on our surgical database. We were able to retrieve their folders 
from our records department and their radiographs were available on our 
digital PACS (picture archiving and communication system). 
35 
Only fractures sustained due to falling from standing height or lower (bed or 
chair) with radiographic osteopenia were included. 
Pathological and high energy fractures were excluded. 
Incomplete clinical records were excluded. 
We examined clinical records to determine the waiting time from admission to 
surgery, pain control and thrombo-prophylaxis strategies, the rate of geriatric 
referrals and the extent of evaluation and management of osteoporosis. 
Formal evaluation of osteoporosis meant that serum Vitamin D, calcium 
levels, erythrocyte sedimentation rate, thyroid function test and parathyroid 
hormone level were all requested with or without a DEXA scan. 
Ethical approval was obtained from our institution's Human Research Ethics 
Committee. 
Results 
We admitted 113 fragility fractures of the hip from 1st January to 31st 
December 2014, 98 clinical records and 98 pelvis radiographs were included 
in the study. The other 15 clinical records were incomplete and were 
therefore excluded. Eighty- three patients (84.7%) were females and 15 
(15.3%) were males (fig1). The mean age was 71.6 years (range 40 - 93 ) 
(fig2). The average waiting time from admission to surgery was 49 hours 
(range 9-120). All patients had low dose morphine, tramadol and 
paracetamol prescribed for pain control. They all had low molecular weight 
heparin 40 mg subcutaneously and compression stockings prescription for 
thrombo-prophylaxis. Two patients (2.04%) had a DEXA scan done for bone 
mineral density assessment but none of the patients were formally 
investigated for osteoporosis. No patient had a vitamin D or calcium 
prescription in hospital or on subsequent visits. Bisphosphonates were not 
prescribed for any of the patients and none of the patients were referred to 
the geriatric department.(fig3) 
Fifteen (15.3%) patients presented with a history of a previous fragility 
fracture of the contra-lateral hip and 2 of them had 2 previous major fragility 
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fractures (spine and proximal humerus fractures) without any previous 
assessment or management of osteoporosis. 
Discussion 
The results of this study have emphasised that fragility fractures are not only 
an injury of the female gender but males also can be affected. In our study 
15% of cases were males. On further analysis 3% of the patients who were 
under 50 years of age were males. Despite their lower incidence of fragility 
fractures male patients tend to have poorer outcomes compared to 
postmenopausal women.11 
The aim of treatment of fragility fractures of the hip is to restore the patient's 
pre-injury activity level while minimizing morbidity and mortality and laying out 
a plan for secondary prevention of future fragility fractures. 
To achieve this aim a multidisciplinary approach is required to cater for the 
wide variety of physiological disturbances that are often found in these 
patients. 
The emergency physician would usually refer these patients straight to the 
orthopaedic surgeon and the later becomes a key player in the 
multidisciplinary team that will be looking after these patients. 
Ekman in his review article gives a check list of management priorities that 
the orthopaedic surgeon must satisfy while treating fragility fractures of the 
hip. This check list ensures that patients receive a holistic treatment for a 
positive outcome.12 
The multidisciplinary approach is aimed at reducing peri-operative 
complications seen in patients being treated for fragility fractures of the hip. 
These complications include Deep Vein Thrombosis (DVT), pulmonary 
infections, delirium, decubitus pressure ulcers and cardiovascular events. 
The current recommendations for the treatment of fragility fractures of the hip 
involve a specialized pain management strategy, thrombo-prophylaxis, early 
surgery (within 48 hours of admission), referral to geriatricians, physical 
therapists, dieticians and endocrinologists for a multidisciplinary care.4 
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The results of our study show that there was urgency in the surgical 
management of FFH with an average waiting time of 49 hours from 
admission to surgery. Patients who did not require advanced 
cardiopulmonary investigations for their pre-operative work up could get to 
theatre within 9 hours of admission into hospital. However patients who 
required extensive cardiopulmonary evaluation and stabilization could wait up 
to 120 hours. Our waiting time to surgery signals that our casualty personnel, 
orthopaedic surgeons and anaesthetists understand the urgency to surgically 
stabilise these fractures and allow early rehabilitation.  
Special investigations such as cardiac echography and lung function test 
constituted the major reasons for delayed surgical fixation of the hip fracture. 
Patients admitted on a Friday evening would wait till the next Monday for a 
cardiac echography or a lung function test to be done if necessitated by their 
cardiopulmonary conditions. 
 In a prospective observational study Pioli reported that the one year mortality 
risk increased by 12% per day of surgical delay.13 It is therefore imperative 
that all unnecessary delays to surgery be proactively avoided to prevent 
morbidity and mortality. 
All our patients had low dose morphine, tramadol and paracetamol 
prescription for pain control. This conservative approach undertreats pain 
and predisposes to pain induced delirium. In a single centre study, initiation 
of a standardized pain control program including the pre-operative use of 
femoral nerve blocks, avoidance of general anaesthesia and liberal use of 
oral intakes (food and oral fluids) pre-operatively resulted in much lower peri-
operative complications (pneumonia, urinary tract infection, delirium) 
compared to pre-programme rates.14 
Deep vein thrombosis (DVT) is another major complication that must be 
prevented in this fragile population of patients. A meta-analysis of 
prospective cohorts in Asian patients with hip fractures revealed that 26% of 
patients not on DVT prophylaxis developed a postoperative DVT.15 It is 
therefore recommended that all patients receive effective DVT prophylaxis. 
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All our patients had low molecular weight heparin (Enoxaparin 40 mg once 
daily subcutaneously) prescribed for DVT prophylaxis. This was combined 
with a prescription of compression stockings for all patients.  
Fifty-one percent of reviewed cases were patients above the age of 75. In  
this age group the incidence of fragility fracture rises significantly.16 This  
probably due to a combination of frailty and senile osteoporosis. These 
patients need to be seen by a geriatrician who will optimise their medical 
condition while the orthopaedic surgeon focuses on surgical treatment. None 
of our patients were referred to a geriatricians. 
A quarter of patients admitted with fragility fractures will develop delirium.17 
Predisposing factors for delirium include male gender, multiple co-
morbidities, low body mass index (BMI), prolonged surgery and general 
anaesthesia.17 Post-operative delirium is usually transient but it can persist 
for more than 4 weeks in 20% of patients. Delirium is associated with lower 
functional recovery and higher mortality rate at 1 year.18 Therefore the 
prevention of delirium becomes of paramount importance. 
The literature supports that early referral to geriatricians is associated with 
lower rate of postoperative delirium.19,20  Where the service of a geriatrician is 
lacking a specialist physician with interest in the field of geriatrics can be 
consulted for the management of these patients. 
By definition a FFH implies a diagnosis of osteoporosis. According to the 
WHO criteria, a diagnosis of osteoporosis is made when a patient has a T 
score lower than -2.5 or when a patient presents with a typical fragility 
fracture defined as a fracture occurring after a fall from standing height or 
lower and has osteopenia on plain radiographs.8 This definition excludes 
pathological fractures due to malignancies and infections. Osteoporosis must 
be investigated, classified and appropriately treated for every patient 
presenting with a FFH. 
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In our study only 2 out of 98 patients had a DEXA scan done with no other 
osteoporosis investigations ordered.  None of our patients were treated for 
osteoporosis. This finding outlines the fact that orthopaedic surgeons satisfy 
themselves with a well performed fracture fixation as seen on postoperative 
radiographs and forget to facilitate or initiate the management of frailty and 
osteoporosis. 
Similar studies conducted in Europe and in the United States have reported 
the same trend. Very few patients presenting with fragility fractures of the hip 
will actually get treated for osteoporosis. Rabenda et al reported that only 
4.6% of patients with fragility fractures of the hip were fully treated for 
osteoporosis in their study4 and Jennings reported a 2% rate of osteoporosis 
treatment in patients admitted for fragility fractures of the hip.6 
Osteoporosis work up  starts with a DEXA scan which provides patient’s T 
score for the diagnosis and a baseline bone mineral density(BMD) to monitor 
response to treatment. However the lack of a DEXA scan should not hinder 
osteoporosis treatment for patients presenting with FFH. 
Laboratory investigations will help exclude any possible cause of secondary 
osteoporosis and the following tests should be requested for all patients 
under investigation for osteoporosis:7, 21 
1.Erythrocyte sedimentation rate (ESR)
2.Thyroid function test
3.Serum parathyroid hormone (PTH) level
4.Serum calcium level
5.Vitamin D level
6.Protein electrophoresis for a myeloma screen when clinically suspected.
The management plan will differ between the 2 main forms of osteoporosis, 
namely: primary and secondary osteoporosis. 
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General nutritional and lifestyle modifications will apply to both primary and 
secondary osteoporosis and include regular physical activity, adequate intake 
of calcium, vitamin D and proteins. 
A daily intake of at least 1.2g of calcium and 800 IU of vitamin D has been 
shown to reduce the relative risk of falls and fragility fractures more in the 
institutionalized elderly patients than in the community dwellers.1, 22  
Sarcopenia is being increasingly recognized as an independent risk factor for 
falls and fragility fractures.23 Physiotherapists and dieticians work together to 
correct sarcopenia and optimize physical performance of these patients for a 
better clinical outcome. 
Smoking needs to be stopped and alcohol consumption moderated. 
Pharmacological treatment will depend on the type of primary osteoporosis 
being addressed. 
Postmenopausal osteoporosis may benefit from hormone replacement 
therapy early on but as senile osteoporosis sets in bisphosphonates therapy 
will be required to maintain adequate bone mineral density. 
Once all causes of secondary osteoporosis have been excluded 
bisphosphonate therapy is indicated. High risk patients as determined by the 
applicable Fracture Risk Assessment Tool (FRAX index) are also eligible for 
treatment 22,24. The FRAX tool combines patient’s specific bone mineral 
density and clinical risk factors such as age, gender, body mass index(BMI), 
history of fragility fractures, history of maternal hip fracture and current 
smoking status to calculate a ten-year risk of hip or other osteoporosis 
related fractures for the patient being assessed. This tool is country 
specific.24Most commonly oral alendronate 70 mg weekly or zolendronic acid 
5mg IV yearly is prescribed.25 
 Alendronate has been proven to reduce the vertebral fracture risk by 60% 
and hip fracture risk by 30%.25 Zolendronic acid once yearly  study showed a 
70% risk reduction of morphometric vertebral fractures and 41% risk 
reduction of hip fractures at 36 months.26  
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The most debated side effects of bisphosphonates are atypical femur 
fractures, osteonecrosis of the jaw and delayed or impaired fracture 
healing.22,25 
The rate of atypical femur  fractures varies in the literature but the known fact 
is that the incidence shows an exponential increase with the increase in the 
number of years of continuous bisphosphonates treatment.25 
Osteoclastic activity remains inhibited for a few years after discontinuation of 
bisphosphonates use. This allows  for a “drug holiday” to minimise the rate of 
atypical fractures.26 
In the setting of osteoporosis treatment , the rate of osteonecrosis of the jaw 
is much lower than that of atypical femoral fractures.25, 26 
 A meta-analysis of 8 randomized controlled trials found that bisphosphonate 
treatment did not impair or delay fracture healing at short term (3 months) or 
long term (more than 12 months).27 
Other recent and not widely available pharmacological agents for the 
treatment of osteoporosis include parathyroid hormone (Forteo, Teriparatide), 
Denosumab (Prolia), Strontium Ranelate (Protos) and Cathepsin K 
inhibitors.28,29,30,31 
To simply provide a sound and early surgical fixation of the hip fracture and 
not address the underlying osteoporosis, frailty and certain possible causes 
of falls is in a way failing to provide the holistic and comprehensive 
management that these patients need. 
The orthopaedic surgeon is most often the first specialist to see these 
patients and it is his or her responsibility to make early and appropriate 
referrals to geriatricians, physicians, endocrinologists, physical therapists and 
dieticians. These other team players will help optimize patients’ medical 
condition to allow early surgery, early rehabilitation, optimal investigations, 
prevention and treatment of peri-operative complications and lay out a plan 
for osteoporosis treatment. 
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The literature shows that less than 10% of patients presenting to major 
trauma centres with fragility fractures of the hip are fully evaluated and 
managed for osteoporosis. This outlines the need to increase awareness of 
osteoporosis management in orthopaedic trauma centres worldwide.4,6,32 
This study was the first step of our quality assessment project for the 
management of fragility fractures of the hip at our institution. It has led to the 
development of a strict management protocol and the genesis of an ortho-
geriatric unit called GOGO (Geriatric Orthopaedic and Generalized 
Osteoporosis) that functions as our fracture liaison service for a focused and 
improved care for fragility fractures of the hip as the primary target. 
The ortho-geriatric unit aims at providing an integrated service where 
orthopaedic surgeons and geriatricians provide an integrated care without the 
frustration of lengthy telephonic referrals. Geriatricians see these patients as 
their own patients and not as orthopaedic patients. 
There are various models of integrated fragility fracture care available, each 
institution treating these fractures should adopt a suitable model that 
promotes an integrated multidisciplinary approach and optimal treatment of 
these fragile patients for secondary prevention of fragility fractures. 
CONCLUSION 
The vast majority of our patients had their hip fractures surgically fixed within 
the recommended time frame. Our management approach lacked the 
multidisciplinary integration that is recommended for these patients. 
Osteoporosis and frailty were largely not addressed. The results of this study 
served as a platform to increase awareness of osteoporosis and frailty 
management as part of a multidisciplinary care for fragility fractures of the 
hip. We have subsequently formed a multidisciplinary unit in an effort to 
address our treatment deficiencies and to improve these patients’ outcomes. 
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Fig 1   Gender Distribution. 
 85% of patients were female and 15% were males. 
Fig 2   Age distribution. The majority of patients were older than 75 years of age 
Fig 3 Measures of standard of care: only 2% of patients investigated for 
osteoporosis and no geriatric referrals 
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